Treatment with an oral direct thrombin inhibitor decreases platelet activity but increases markers of inflammation in patients with myocardial infarction

Journal of Internal Medicine

Volumn 270, Issue 3, 2011, Pages 215-223

  Christersson, C ^a   Oldgren, J ^a   Wallentin, L ^a   Siegbahn, A ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

Anticoagulation treatment; Antithrombotic treatment; Inflammation; Myocardial infarction; Platelets

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 10; INTERLEUKIN 18; LOW MOLECULAR WEIGHT HEPARIN; PADGEM PROTEIN; PLACEBO; THROMBIN INHIBITOR; THROMBOPLASTIN; XIMELAGATRAN;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; BLOOD CLOTTING; BLOOD SAMPLING; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG WITHDRAWAL; FEMALE; HEART INFARCTION; HUMAN; INFLAMMATION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOEMBOLISM;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTITHROMBINS; ASPIRIN; AZETIDINES; BENZYLAMINES; BIOLOGICAL MARKERS; BLOOD PLATELETS; C-REACTIVE PROTEIN; COMORBIDITY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INFLAMMATION; INTERLEUKIN-10; INTERLEUKIN-18; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; P-SELECTIN; PLATELET ACTIVATION; RISK FACTORS; THROMBOPLASTIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 80051562671     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2011.02354.x     Document Type: Article

References (49)

1. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-95.
2. Gawaz M. Role of platelets in coronary thrombosis and reperfusion of ischemic myocardium. Cardiovasc Res 2004; 61: 498-511.
3. Ikeda H, Takajo Y, Ichiki K et al. Increased soluble form of P-selectin in patients with unstable angina. Circulation 1995; 92: 1693-6.
4. Suefuji H, Ogawa H, Yasue H et al. Increased plasma tissue factor levels in acute myocardial infarction. Am Heart J 1997; 134: 253-9.
5. Osterud B, Bjorklid E. Sources of tissue factor. Semin Thromb Hemost 2006; 32: 11-23.
6. Giesen PL, Rauch U, Bohrmann B et al. Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci USA 1999; 96: 2311-5.
7. Blann AD, Lip GY, Beevers DG, McCollum CN. Soluble P-selectin in atherosclerosis: a comparison with endothelial cell and platelet markers. Thromb Haemost 1997; 77: 1077-80.
8. Fijnheer R, Frijns CJ, Korteweg J et al. The origin of P-selectin as a circulating plasma protein. Thromb Haemost 1997; 77: 1081-5.
9. Semenov AV, Romanov YA, Loktionova SA et al. Production of soluble P-selectin by platelets and endothelial cells. Biochemistry (Mosc) 1999; 64: 1326-35.
10. Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. Frisc study group. Fragmin during instability in coronary artery disease. N Engl J Med 2000; 343: 1139-47.
11. Malarstig A, Eriksson P, Hamsten A, Lindahl B, Wallentin L, Siegbahn A. Raised interleukin-10 is an indicator of poor outcome and enhanced systemic inflammation in patients with acute coronary syndrome. Heart 2008; 94: 724-9.
12. Blankenberg S, Tiret L, Bickel C et al. Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation 2002; 106: 24-30.
13. Mallat Z, Corbaz A, Scoazec A et al. Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability. Circulation 2001; 104: 1598-603.
14. Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-51.
15. Wallentin L, Wilcox RG, Weaver WD et al. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the esteem randomised controlled trial. Lancet 2003; 362: 789-97.
16. Schulman S, Kearon C, Kakkar AK et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361: 2342-52.
17. Niessen F, Schaffner F, Furlan-Freguia C et al. Dendritic cell par1-s1p3 signalling couples coagulation and inflammation. Nature 2008; 452: 654-8.
18. Stephenson DA, Toltl LJ, Beaudin S, Liaw PC. Modulation of monocyte function by activated protein c, a natural anticoagulant. J Immunol 2006; 177: 2115-22.
19. Nishimura T, Myles T, Piliponsky AM, Kao PN, Berry GJ, Leung LL. Thrombin-activatable procarboxypeptidase b regulates activated complement c5a in vivo. Blood 2007; 109: 1992-7.
20. Olsson SB. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (sportif iii): randomised controlled trial. Lancet 2003; 362: 1691-8.
21. Christersson C, Oldgren J, Bylock A, Wallentin L, Siegbahn A. Long-term treatment with ximelagatran, an oral direct thrombin inhibitor, persistently reduces the coagulation activity after a myocardial infarction. J Thromb Haemost 2005; 3: 2245-53.
22. Christersson C, Johnell M, Siegbahn A. The influence of direct thrombin inhibitors on the formation of platelet-leukocyte aggregates and tissue factor expression. Thromb Res 2010; 126: e327-33.
23. Kaiser B, Koza M, Walenga JM, Fareed J. Flow cytometric evaluation of the effect of various thrombin inhibitors on platelet activation in whole blood. Thromb Res 1996; 82: 257-63.
24. Nylander S, Mattsson C. Thrombin-induced platelet activation and its inhibition by anticoagulants with different modes of action. Blood Coagul Fibrinolysis 2003; 14: 159-67.
25. Busch G, Steppich B, Sibbing D et al. Bivalirudin reduces platelet and monocyte activation after elective percutaneous coronary intervention. Thromb Haemost 2009; 101: 340-4.
26. Wolzt M, Bostrom SL, Svensson M, Wahlander K, Grind M, Sarich TC. Effects of the oral direct thrombin inhibitor ximelagatran on P-selectin expression and thrombin generation in atrial fibrillation. Pathophysiol Haemost Thromb 2003; 33: 68-74.
27. Hulthe J, McPheat W, Samnegard A, Tornvall P, Hamsten A, Eriksson P. Plasma interleukin (il)-18 concentrations is elevated in patients with previous myocardial infarction and related to severity of coronary atherosclerosis independently of c-reactive protein and il-6. Atherosclerosis 2006; 188: 450-4.
28. Bae JS, Rezaie AR. Protease activated receptor 1 (par-1) activation by thrombin is protective in human pulmonary artery endothelial cells if endothelial protein c receptor is occupied by its natural ligand. Thromb Haemost 2008; 100: 101-9.
29. Hoffmann JN, Vollmar B, Laschke MW, Fertmann JM, Jauch KW, Menger MD. Microcirculatory alterations in ischemia-reperfusion injury and sepsis: effects of activated protein c and thrombin inhibition. Crit Care (London, England) 2005; 9(Suppl 4): S33-7.
30. Gerdes N, Sukhova GK, Libby P, Reynolds RS, Young JL, Schonbeck U. Expression of interleukin (il)-18 and functional il-18 receptor on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for atherogenesis. J Exp Med 2002; 195: 245-57.
31. Yamaoka-Tojo M, Tojo T, Masuda T et al. C-reactive protein-induced production of interleukin-18 in human endothelial cells: a mechanism of orchestrating cytokine cascade in acute coronary syndrome. Heart Vessels 2003; 18: 183-7.
32. Mallat Z, Besnard S, Duriez M et al. Protective role of interleukin-10 in atherosclerosis. Circ Res 1999; 85: e17-24.
33. Pinderski Oslund LJ, Hedrick CC, Olvera T et al. Interleukin-10 blocks atherosclerotic events in vitro and in vivo. Arterioscler Thromb Vasc Biol 1999; 19: 2847-53.
34. Chalikias GK, Tziakas DN, Kaski JC et al. Interleukin-18: interleukin-10 ratio and in-hospital adverse events in patients with acute coronary syndrome. Atherosclerosis 2005; 182: 135-43.
35. Nold M, Goede A, Eberhardt W, Pfeilschifter J, Muhl H. IL-18 initiates release of matrix metalloproteinase-9 from peripheral blood mononuclear cells without affecting tissue inhibitor of matrix metalloproteinases-1: suppression by tnf alpha blockage and modulation by IL-10. Naunyn Schmiedebergs Arch Pharmacol 2003; 367: 68-75.
36. Heeschen C, Dimmeler S, Hamm CW et al. Serum level of the antiinflammatory cytokine interleukin-10 is an important prognostic determinant in patients with acute coronary syndromes. Circulation 2003; 107: 2109-14.
37. Oldgren J, Fellenius C, Boman K et al. Influence of prolonged dalteparin treatment on coagulation, fibrinolysis and inflammation in unstable coronary artery disease. J Intern Med 2005; 258: 420-7.
38. Berk BC, Weintraub WS, Alexander RW. Elevation of c-reactive protein in "active" coronary artery disease. Am J Cardiol 1990; 65: 168-72.
39. Whitman SC, Ravisankar P, Daugherty A. Interleukin-18 enhances atherosclerosis in apolipoprotein e(-/-) mice through release of interferon-gamma. Circ Res 2002; 90: E34-8.
40. Fiessinger JN, Huisman MV, Davidson BL et al. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. JAMA 2005; 293: 681-9.
41. Lip GY, Lane DA. Does warfarin for stroke thromboprophylaxis protect against mi in atrial fibrillation patients? Am J Med 2010; 123: 785-9.
42. Celi A, Pellegrini G, Lorenzet R et al. P-selectin induces the expression of tissue factor on monocytes. Proc Natl Acad Sci USA 1994; 91: 8767-71.
43. Weyrich AS, Elstad MR, McEver RP et al. Activated platelets signal chemokine synthesis by human monocytes. J Clin Invest 1996; 97: 1525-34.
44. Christersson C, Johnell M, Siegbahn A. Tissue factor and IL8 production by P-selectin-dependent platelet-monocyte aggregates in whole blood involves phosphorylation of lyn and is inhibited by IL10. J Thromb Haemost 2008; 6: 986-94.
45. Belliard A, Mauco G, Bonnet ML, Hauet T, Macchi L. Melagatran prevents tissue factor expression in human platelet-monocyte heterotypic complexes. Cell Mol Biol (Noisy-le-Grand, France) 2008; 54(Suppl): OL1077-82.
46. George FD. Microparticles in vascular diseases. Thromb Res 2008; 122(Suppl 1): S55-9.
47. Butenas S, Orfeo T, Mann KG. Tissue factor in coagulation: which? Where? When? Arterioscler Thromb Vasc Biol 2009; 29: 1989-96.
48. Novick D, Kim SH, Fantuzzi G, Reznikov LL, Dinarello CA, Rubinstein M. Interleukin-18 binding protein: a novel modulator of the th1 cytokine response. Immunity 1999; 10: 127-36.
49. Eriksson BI, Dahl OE, Rosencher N et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007; 370: 949-56.